ICM
VTRS icon

Invenomic Capital Management’s Viatris VTRS Stock Holding History

Invenomic Capital Management’s Portfolio VTRS Stock Details VTRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.6M Sell
1,738,790
-1,490,322
-46% -$23.1M 1.65% 18
2026
Q1 		$43.6M Sell
3,229,112
-2,364,496
-42% -$33.1M 2% 10
2025
Q4 		$69.6M Buy
5,593,608
+180,499
+3% +$1.95M 3.24% 1
2025
Q3 		$53.6M Buy
5,413,109
+769,934
+17% +$7.49M 2.59% 5
2025
Q2 		$41.5M Sell
4,643,175
-1,793,457
-28% -$15.2M 2.35% 3
2025
Q1 		$56.1M Buy
6,436,632
+3,176,201
+97% +$33.3M 2.83% 1
2024
Q4 		$40.6M Sell
3,260,431
-499,112
-13% -$6.13M 1.93% 6
2024
Q3 		$43.6M Sell
3,759,543
-531,051
-12% -$6.13M 2.4% 4
2024
Q2 		$45.6M Buy
4,290,594
+338,279
+9% +$3.74M 2.22% 6
2024
Q1 		$47.2M Sell
3,952,315
-1,860,565
-32% -$22.4M 2.51% 3
2023
Q4 		$63M Sell
5,812,880
-1,139,765
-16% -$10.9M 2.87% 4
2023
Q3 		$68.6M Buy
6,952,645
+1,388,362
+25% +$14.5M 2.88% 3
2023
Q2 		$55.5M Buy
5,564,283
+1,661,373
+43% +$15.9M 2.81% 4
2023
Q1 		$37.5M Buy
3,902,910
+1,935,438
+98% +$21.5M 2.12% 11
2022
Q4 		$21.9M Buy
1,967,472
+914,106
+87% +$9.55M 1.49% 19
2022
Q3 		$8.97M Buy
+1,053,366
New +$10.4M 0.77% 46
2021
Q1 		– Sell
-110,657
Closed -$2.07M – 160
2020
Q4 		$2.07M Buy
110,657
+15,538
+16% +$253K 0.53% 37
2020
Q3 		$1.41M Sell
95,119
-10,136
-10% -$162K 0.78% 44
2020
Q2 		$1.69M Hold
105,255
– – 1.25% 25
2020
Q1 		$1.57M Sell
105,255
-23,887
-18% -$458K 1.28% 24
2019
Q4 		$2.6M Buy
+129,142
New +$2.4M 1.04% 42

Other funds holding VTRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DSA
Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invenomic Capital Management's VTRS Position: Q2 2026 in Review

Invenomic Capital Management reduced its Viatris (VTRS) stake by 46% in Q2 2026, selling an estimated $23.1M and leaving 1,738,790 shares worth $27.6M. The position accounts for 1.65% of the portfolio, ranked #18.

Invenomic Capital Management first reported a position in VTRS in Q4 2019 and has held it in 21 quarters since. The position peaked at $69.6M in Q4 2025. 1,026 funds tracked by Wall St. Rank hold VTRS as of Q2 2026.

  • Invenomic Capital Management held 1,738,790 shares of Viatris worth $27.6M as of Q2 2026.
  • Invenomic Capital Management sold 1,490,322 Viatris shares in Q2 2026, an estimated $23.1M.
  • Viatris made up 1.65% of Invenomic Capital Management's portfolio in Q2 2026, its #18 holding.
  • Invenomic Capital Management first reported a position in Viatris in Q4 2019 and has held it in 21 quarters since.
  • Invenomic Capital Management's Viatris position peaked at $69.6M in Q4 2025.
  • 1,026 funds tracked by Wall St. Rank held Viatris as of Q2 2026.

Based on Invenomic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.